Atherosclerosis
Volume 186, Issue 1 , Pages 65-73 , May 2006

Persistent liver expression of murine apoA-l using vectors based on adeno-associated viral vectors serotypes 5 and 1

  • Ken Kitajima

      Affiliations

    • Institute for Translational Medicine and Therapeutics, University of Pennsylvania Medical Center, 654 BRBII/III Labs, 421 Curie Blvd, Philadelphia, PA 19104-6160, USA
    • ,
  • Dawn H.L. Marchadier

      Affiliations

    • Institute for Translational Medicine and Therapeutics, University of Pennsylvania Medical Center, 654 BRBII/III Labs, 421 Curie Blvd, Philadelphia, PA 19104-6160, USA
    • ,
  • Haim Burstein

      Affiliations

    • Targeted Genetics Corporation, 1100 Olive Way, Suite 100, Seattle, WA 98101, USA
    • ,
  • Daniel J. Rader

      Affiliations

    • Institute for Translational Medicine and Therapeutics, University of Pennsylvania Medical Center, 654 BRBII/III Labs, 421 Curie Blvd, Philadelphia, PA 19104-6160, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 215 573 4176; fax: +1 215 573 8606.

Received 13 January 2005 ,Revised 1 July 2005 ,Accepted 11 July 2005.

References 

  1. Rader DJ. High-density lipoproteins and atherosclerosis. Am J Cardiol. 2002;90:62i–70i
  2. Barter P, Kastelein J, Nunn A, Hobbs R. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis. 2003;168:195–211
  3. Benoit P, Emmanuel F, Caillaud JM, et al. Somatic gene transfer of human ApoA-l inhibits atherosclerosis progression in mouse models. Circulation. 1999;99:105–110
  4. Van Linthout S, Collen D, De Geest B. Effect of promoters and enhancers on expression, transgene DNA persistence, and hepatotoxicity after adenoviral gene transfer of human apolipoprotein A-l. Hum Gene Ther. 2002;13:829–840
  5. Tangirala RK, Tsukamoto K, Chun SH, et al. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-l in mice. Circulation. 1999;100:1816–1822
  6. Mingozzi F, Schuttrumpf J, Arruda VR, et al. Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector. J Virol. 2002;76:10497–10502
  7. Snyder RO, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med. 1999;5:64–70
  8. Chen SJ, Rader DJ, Tazelaar J, et al. Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low-density lipoprotein receptor. Mol Ther. 2000;2:256–261
  9. Samulski RJ, Berns KL, Tan M, Muzyczka N. Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci USA. 1982;79:2077–2081
  10. Srivastava A, Lusby EW, Berns KI. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol. 1983;45:555–564
  11. Auricchio A, O’Connor E, Weiner D, et al. Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. J Clin Invest. 2002;110:499–504
  12. Auricchio A, Kobinger G, Anand V, et al. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet. 2001;10:3075–3081
  13. Rabinowitz JE, Rolling F, Li C, et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol. 2002;76:791–801
  14. Sandalon Z, Bruckheimer EM, Lustig KH, et al. Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004;78:12355–12365
  15. Hayashi Y, Mori Y, Janssen OE, et al. Human thyroxine-binding globulin gene: complete sequence and transcriptional regulation. Mol Endocrinol. 1993;7:1049–1060
  16. Rouet P, Raguenez G, Tronche F, et al. A potent enhancer made of clustered liver-specific elements in the transcription control sequences of human alpha 1-microglobulin/bikunin gene. J Biol Chem. 1992;267:20765–20773
  17. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150:76–85
  18. Daly TM, Vogler C, Levy B, et al. Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc Natl Acad Sci USA. 1999;96:2296–22300
  19. Chao H, Mao L, Bruce AT, Walsh CE. Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood. 2000;95:1594–1599
  20. Chao H, Liu Y, Rabinowitz J, et al. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther. 2000;2:619–623
  21. Jung SC, Han IP, Limaye A, et al. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc Natl Acad Sci USA. 2001;98:2676–2681
  22. Monahan PE, Samulski RJ. AAV vectors: is clinical success on the horizon?. Gene Ther. 2000;7:24–30
  23. Carter BJ, Burstein H, Peluso RW. Adeno-associated virus and AAV vectors for gene therapy. In:  Templeton Nancy Smyth editors. Gene and cell therapy: therapeutic mechanisms and strategies. 2nd ed. (revised and expanded). New York, NY: Marcel Dekker; 2004;p. 71–101
  24. Xiao W, Chirmule N, Berta SC, et al. Gene therapy vectors based on adeno-associated virus type 1. J Virol. 1999;73:3994–4003
  25. Hauck B, Chen L, Xiao W. Generation and characterization of chimeric recombinant AAV vectors. Mol Ther. 2003;7:419–425

PII: S0021-9150(05)00465-X

doi: 10.1016/j.atherosclerosis.2005.07.009

Atherosclerosis
Volume 186, Issue 1 , Pages 65-73 , May 2006

Article Tools

* Image Usage & Resolution